Drug Eluting Stents Market, by Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), by Coating Type (Polymer-based Coatings and Polymer-free Coatings), by Application (Coronary Artery Disease and Peripheral Artery Disease), by End

Drug Eluting Stents Market, by Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), by Coating Type (Polymer-based Coatings and Polymer-free Coatings), by Application (Coronary Artery Disease and Peripheral Artery Disease), by End User (Cardiology Centers, Ambulatory Surgery Centers (ASCs), and Hospitals), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Coronary artery stents are small cylindrical device that helps in improving blood flow through arteries to the heart by reducing the blockages in artery. Stents are usually used in the treatment of coronary angioplasty or percutaneous coronary intervention producers. The drug eluting stents types include bare metal coronary artery stents, coronary artery restenosis, coronary artery stents, coronary revascularization, and others. Coronary artery stents are more beneficial for the patients suffering from coronary artery diseases such as myocardial infarction.
Market Dynamics
Manufacturers are focused on developing and launching new products and receiving product approval from regulatory bodies. For instance, in April 2021, Shanghai-based MicroPort Medical (Group) Co., Ltd. received CE (Conformité Européenne) Mark for ‘Firehawk Liberty’, a new generation rapamycin target eluting coronary stent system.
Furthermore, in May 2017, key players such as Medtronic Plc., launched Resolute Onyx drug-eluting stent that provides physicians with additional 4.5mm and 5mm sizes to treat patients with large coronary anatomies in the U.S. Such product launches and product approvals are expected to boost the global drug eluting stents market growth over the forecast period.
Rising incidence of cardiovascular disease, heart failure, and coronary heart disease cases, owing to increasing prevalence of diabetes, obesity, and high blood pressure globally is expected to fuel global drug eluting stents market growth over the forecast period. For instance, according to the American Heart Association (AHA) 2016, around 15.5 million people ≥20 years of age in the U.S. suffered from coronary heart disease. Moreover, according to the same source, it is estimated that each day, every 42 seconds, an American suffered with Myocardial Infraction.
Moreover, increasing prevalence of cardiac diseases is expected to drive growth of the market over the forecast period. For instance, according to the World Health Organization (WHO), in 2017, globally 17.9 million people had death from cardiovascular diseases such as coronary heart disease, peripheral arterial disease, and others.
Key features of the study:
This report provides in-depth analysis of the global drug eluting stents market and provides market size (US$ Mn) and cumulative annual growth rate (CAGR) (%) for the forecast period (2022 - 2028), considering 2021 as a base year.
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, pipeline products, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global drug eluting stents market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launches, market expansion, and marketing tactics
The global drug eluting stents market report caters to various stakeholders in this industry, including investors, product developers, distributors, healthcare companies, research institutes, medical device companies, new entrants, and financial analysts
Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the global drug eluting stents market
Detailed Segmentation:
Drug Eluting Stents Market, By Drug
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
Drug Eluting Stents Market, By Coating Type
Polymer-based Coatings
Polymer-free Coatings
Drug Eluting Stents Market, By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
Drug Eluting Stents Market, By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
Drug Eluting Stents Market, By Region
North America
By Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
By Coating Type:
Polymer-based Coatings
Polymer-free Coatings
By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
By Country:
U.S.
Canada
Europe
By Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
By Coating Type:
Polymer-based Coatings
Polymer-free Coatings
By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
By Coating Type:
Polymer-based Coatings
Polymer-free Coatings
By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
By Coating Type:
Polymer-based Coatings
Polymer-free Coatings
By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
By Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
By Coating Type:
Polymer-based Coatings
Polymer-free Coatings
By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
By Country:
GCC
Israel
Rest of Middle East
Africa
By Drug:
Sirolimus
Paclitaxel
Zotarolimus
Everolimus
Biolimus
Others
By Coating Type:
Polymer-based Coatings
Polymer-free Coatings
By Application:
Coronary Artery Diseases
Peripheral Artery Diseases
By End User:
Cardiology Centers
Ambulatory Surgery Centers (ASCs)
Hospitals
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Boston Scientific Corporation *
Company Overview
Product Portfolio
Market Presence
Financial Overview
Key Developments
Strategies
Medtronic, Plc.
Abbott Laboratories
Biosensors International Group
Biotronik
Lepu Medical Technology
Terumo Medical Corporation
Cook Medical
Shandong JW Medical Systems
Stentys
Abbott Vascular Inc.
AlviMedica Medical Technologies Inc.
Amaranth Medical, Inc.
HangZhou HuaAn Biotechnology Co.,Ltd
XTENT, Inc.
Cardionovum GmbH
Cordis Corporation
Kyoto Medical Planning Co., Ltd.